Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.
Cushing
Daniel J
DJ
Prism Pharmaceuticals, Inc., King of Prussia, PA, USA. dcushing@prismpharma.com
Cooper
Warren D
WD
Cohen
Marlene L
ML
McVoy
Julie R S
JR
Sobel
Michael
M
Harris
Robert B
RB
D000818:Animals; D000925:Anticoagulants / Q000037:antagonists & inhibitors / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006493:Heparin / Q000494:pharmacology*; D006494:Heparin Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008297:Male; D010314:Partial Thromboplastin Time; D010455:Peptides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D011479:Protamines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
D000925:Anticoagulants; D006494:Heparin Antagonists; C551453:PM102 peptide; D010455:Peptides; D011479:Protamines; D006493:Heparin